Press Release Archives

  Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts     June 11, 2024   WARREN, N.J., Tevogen Bio Holdings (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology,Continue reading “Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts”

  Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event   June 7, 2024   WARREN, N.J., Tevogen Bio Holdings (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerfulContinue reading “Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event”

  Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2   June 6, 2024   WARREN, N.J., Tevogen Bio Holdings (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, todayContinue reading “Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2”

  Tevogen Bio Reports First Quarter 2024 Financial Results   Confirms liability elimination of $94.9 million and discloses $11.3 million of net income Reports net cash used for operating activities was $2.1 million Reiterates commitment to both patients and shareholders   May 29, 2024   WARREN, N.J., Tevogen Bio Holdings (“Tevogen” or “Tevogen Bio”) (Nasdaq:Continue reading “Tevogen Bio Reports First Quarter 2024 Financial Results”

  Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives     William Keane, Vice President of Strategic Initiative, Tevogen Bio   May 16, 2024   WARREN, N.J., Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified TContinue reading “Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives”

  Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives   Supports expansion of Tevogen’s ExacTcellTM platform toward additional clinical trials Bolsters a financial path to positive cashflow and minimizes dilution   May 10, 2024   WARREN, N.J., Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneerContinue reading “Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives”

  Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives   Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results and clarify key financial items   May 1, 2024   WARREN, N.J., TevogenContinue reading “Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives”

  Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments   Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities. The converted common stock is included in the company’s total 165 million outstanding shares. The Tevogen.ai initiative aims to harnessContinue reading “Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments”

  Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers   Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities. Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additionalContinue reading “Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers”

  Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development     April 3, 2024   WARREN, N.J., Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development. Mr. Shah, a Wall StreetContinue reading “Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development”